Xtant Medical Announces Second Quarter 2019 Financial Results


BELGRADE, MT, August 8, 2019 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2019.


Second Quarter 2019 Financial Highlights:


  Revenue for the second quarter of 2019 was $15.3 million, compared to $18.7 million for the same prior year period
  Operating expenses in the second quarter of 2019 were $10.5 million, compared to $14.7 million for the same prior year period
  Net loss incurred in the second quarter of 2019 was $1.9 million, compared to a net loss of $5.0 million for the same prior year period
  Non-GAAP Adjusted EBITDA for the second quarter of 2019 was $1.2 million, compared to $0.8 million for the same prior year period


Greg Jensen, VP, Finance and CFO of Xtant Medical, said, “Our efforts to reduce expenses while further enhancing the operational effectiveness of our business resulted in improved cash flow, net loss and adjusted EBITDA during the second quarter, despite softer revenues. We are taking measures designed to stabilize and improve our revenue trajectory, and we plan to implement additional initiatives to support this critical goal during the second half of 2019 and into 2020. These initiatives include a commitment to developing new products, further development and expansion of marketing programs, and continued pursuit of operational improvements intended to assist us in our overall commercial performance.”


Second Quarter 2019 Financial Results


Second quarter 2019 revenue was $15.3 million, compared to $18.7 million for the same period in 2018. This decrease was due primarily to reduced demand for hardware products, which was due in part to effects from the December 2018 recall of the Calix Lumbar Spine Implant System, the termination of an advisory agreement with an entity that provided services to certain customers, and transition of independent sales agents.


Gross margin for the second quarter of 2019 was 64.9%, compared to 66.6% for the same period in 2018. The year-over-year decrease was attributed primarily to inventory reserving and manufacturing overhead absorption.


Operating expenses for the second quarter of 2019 were $10.5 million, compared to $14.7 million for the second quarter of 2018, a decrease of 29.0%. The decrease was primarily attributable to lower sales commissions and travel expenses, restructuring expenses incurred last year, and a decrease in amortization expense related to the impairment of intangible assets that occurred in the fourth quarter of 2018.


Second quarter 2019 net loss was $1.9 million, or $0.15 per share, compared to second quarter 2018 net loss of $5.0 million, or $0.38 per share.




Non-GAAP Adjusted EBITDA for the second quarter of 2019 was $1.2 million compared to $0.8 million for the same period of 2018. The Company defines Adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense, and as further adjusted to add back in or exclude, as applicable, non-cash special charges, provision for losses on inventory and accounts receivable, non-cash compensation, changes in warrant derivative liability, field action expenses, separation related expenses, litigation reserves, and restructuring expenses. A calculation and reconciliation of non-GAAP Adjusted EBITDA to net loss can be found in the attached financial tables.


Conference Call


Xtant Medical will host a webcast and conference call to discuss the second quarter 2019 financial results on Thursday, August 8, 2019 at 9:00 AM ET. To access the webcast, Click Here. To access the conference call, dial 877-407-6184 within the U.S. or 201-389-0877 outside the U.S. A replay of the call will be available at www.xtantmedical.com, under “Investor Info.”


About Xtant Medical Holdings, Inc.


Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.


The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.


Non-GAAP Financial Measures


To supplement the Company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.




Important Cautions Regarding Forward-looking Statements


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as ‘‘expects,’’ ‘‘anticipates,’’ ‘‘intends,’’ ‘‘plans,’’ ‘‘believes,’’ ‘‘estimates,’’ “continue,” “future,” ‘‘will,’’ “potential” similar expressions or the negative thereof, and the use of future dates. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s future operating results and financial performance; the ability to increase or maintain revenue, including the success of the Company’s initiatives to stabilize and increase revenues; the ability to remain competitive; the ability to innovate and develop new products; the effect of recent management changes and the ability to engage and retain qualified personnel; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects, including the recall of the Company’s Calix Lumbar Spine Implant System; timing and results of clinical studies; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to retain and recruit independent sales agents and the impact of the termination of a consulting agreement with an entity that had close relationships with several of customers; the ability to service Company debt and comply with debt covenants; the ability to raise additional financing and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission (SEC) on April 1, 2019 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 anticipated to be filed with the SEC. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.


Investor Relations Contact


David Carey

Lazar Partners Ltd.

Ph: 212-867-1762

Email: dcarey@lazarpartners.com






(In thousands, except number of shares and par value)


   As of
June 30, 2019

As of

December 31, 2018

Current Assets:          
Cash and cash equivalents  $7,318   $6,797 
Trade accounts receivable, net of allowance for doubtful accounts of $1,223 and $2,140, respectively   8,565    9,990 
Inventories, net   15,828    17,301 
Prepaid and other current assets   592    589 
Total current assets   32,303    34,677 
Property and equipment, net   5,600    7,174 
Right-of -use asset, net   2,296    - 
Goodwill   3,205    3,205 
Intangible assets, net   544    573 
Other assets   549    793 
Total Assets  $44,497   $46,422 
Current Liabilities:          
Accounts payable  $3,194   $6,465 
Accrued liabilities   5,867    5,150 
Warrant derivative liability   21    10 
Current portion of lease liability   511    - 
Current portion of financing lease obligations   337    426 
Total current liabilities   9,930    12,051 
Long-term Liabilities:          
Lease liability, less current portion   1,796    - 
Financing lease obligation, less current portion   16    204 
Long-term debt, less issuance costs   73,831    77,939 
Total Liabilities   85,573    90,194 
Stockholders’ Equity (Deficit)          
Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding   -    - 
Common stock, $0.000001 par value; 50,000,000 shares authorized; 13,161,762 shares issued and outstanding as of June 30, 2019 and 13,172,179 shares issued and outstanding as of December 31, 2018   -    - 
Additional paid-in capital   178,707    171,273 
Accumulated deficit   (219,783)   (215,045)
Total Stockholders’ Equity (Deficit)   (41,076)   (43,772)
Total Liabilities & Stockholders’ Equity (Deficit)  $44,497   $46,422 






(Unaudited, in thousands, except number of shares and per share amounts)


   Three Months Ended June 30,   Six Months Ended June 30, 
   2019   2018   2019   2018 
Orthopedic product sales  $15,197   $18,653   $31,883   $36,483 
Other revenue   74    88    114    191 
Total revenue   15,271    18,741    31,997    36,674 
Cost of sales   5,365    6,266    11,278    11,968 
Gross profit   9,906    12,475    20,719    24,706 
Gross profit %   64.9%   66.6%   64.8%   67.4%
Operating expenses                    
General and administrative   4,041    3,498    8,359    6,885 
Sales and marketing   6,072    8,545    12,814    16,894 
Research and development   210    418    472    832 
Depreciation and amortization   146    1,041    305    2,045 
Restructuring expenses   -    1,234    -    1,968 
Total operating expenses   10,469    14,736    21,950    28,624 
Loss from operations   (563)   (2,261)   (1,231)   (3,918)
Other (expense) income                    
Interest expense   (1,301)   (2,820)   (3,319)   (6,366)
Change in warrant derivative liability   4    79    (11)   41 
Other (expense) income   (57)   -    (132)   (12)
Total Other (Expense) Income   (1,354)   (2,741)   (3,462)   (6,337)
Net Loss from Operations Before Provision for Income Taxes   (1,917)   (5,002)   (4,693)   (10,255)
Provision for income taxes                    
Current and deferred   (22)   -    (45)   - 
Net Loss from Operations  $(1,939)  $(5,002)  $(4,738)  $(10,255)
Net loss per share:                    
Basic  $(0.15)  $(0.38)  $(0.36)  $(1.00)
Dilutive  $(0.15)  $(0.38)  $(0.36)  $(1.00)
Shares used in the computation:                    
Basic   13,161,762    13,085,668    13,166,136    10,299,090 
Dilutive   13,161,762    13,085,668    13,166,136    10,299,090 






(Unaudited, in thousands)


   Six Months Ended June 30, 
   2019   2018 
Operating activities:          
Net loss  $(4,738)  $(10,255)
Adjustments to reconcile net loss to net cash provided by operating activities:          
Depreciation and amortization   1,559    3,227 
Loss on disposal of fixed assets   92    205 
Non-cash interest   3,272    6,205 
Non-cash rent expense   11    - 
Non-cash stock option expense / change in derivative warrant liability   172    364 
Provision for losses on accounts receivable and inventory   750    83 
Changes in operating assets and liabilities:          
Accounts receivable   1,403    2,152 
Inventories   955    (388)
Prepaid and other assets   242    1,120 
Accounts payable   (3,481)   (1,948)
Accrued liabilities   717    (421)
Net cash provided by operating activities   954    344 
Investing activities:          
Purchases of property and equipment and intangible assets   (211)   (288)
Proceeds from sale of fixed assets   163    - 
Net cash used in investing activities   (48)   (288)
Financing activities:          
Payments on financing leases   (277)   (167)
Costs associated with either loan or equity transactions   (108)   (3,507)
Proceeds from equity private placement   -    6,810 
Proceeds from issuance of stock   -    1 
Net cash (used in) provided by financing activities   (385)   3,137 
Net change in cash and cash equivalents   521    3,193 
Cash and cash equivalents at beginning of period   6,797    2,856 
Cash and cash equivalents at end of period  $7,318   $6,049 






(Unaudited, in thousands)


   Three Months Ended June 30,   Six Months Ended June 30, 
   2019   2018   2019   2018 
Net Loss  $(1,939)  $(5,002)  $(4,738)  $(10,255)
Other expense   57    -    132    12 
Depreciation and amortization   783    1,700    1,559    3,289 
Interest expense   1,301    2,820    3,319    6,366 
Tax expense   22    -    45    - 
Non-GAAP EBITDA gain (loss)   224    (482)   317    (588)
Non-GAAP EBITDA/Total revenue   1.5%   -2.6%   1.0%   -1.6%
Provision for losses on accounts receivable and inventory   503    29    750    (16)
Non-cash compensation   39    41    161    405 
Change in warrant derivative liability   (3)   (79)   12    (41)
Separation-related expenses   -    55    -    55 
Field action expenses   125    -    125    - 
Litigation reserve   270    -    800    - 
Restructuring expenses   -    1,235    -    1,968 
Non-GAAP Adjusted EBITDA gain (loss)  $1,158   $799   $2,165   $1,783 
Non-GAAP Adjusted EBITDA/Total revenue   7.6%   4.3%   6.8%   4.9%



The following information was filed by Xtant Medical Holdings, Inc. (XTNT) on Thursday, August 8, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Xtant Medical Holdings, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Xtant Medical Holdings, Inc..


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account